LOS ANGELES, June 11, 2021 (GLOBE NEWSWIRE) -- The Global Medical Flexible Packaging Market is expected to grow at a CAGR of around 6.6% from 2020 to 2027 and reach the market value of over US$ 20.5 Bn by 2027.
North America holds a sizable market share in the global medical flexible packaging market. Product demand in North America is being driven by an improving economic outlook and increased barrier material innovation. Furthermore, the strong presence of major companies such as Amcor and Bemis is expected to boost regional growth during the forecast period. Furthermore, as the use of drug delivery systems such as IV bags and nutrition bags grows, so does product demand.
On the other hand, Asia Pacific is expected to have the fastest growing CAGR in the global medical flexible packaging market during the forecast period. This is due to rising product demand from emerging markets like India and China. Rising per capita income, combined with a growing healthcare industry, is also expected to benefit market development. Contract manufacturing will be one of the region's key end-use sectors over the forecast period, providing lucrative growth opportunities for medical flexible packaging manufacturers in the coming years.
DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2665
The declining growth of the pharmaceutical industry in France, Germany, and Italy as a result of shifting manufacturing base to regions with lower manufacturing costs is expected to have a negative impact on the European regional market. However, rising R&D spending in Europe's pharmaceutical industry is expected to indirectly boost product demand over the forecast period.
Market Dynamics
The market is being driven by the expanding pharmaceutical market in emerging economies, as well as the expansion of drug delivery systems. The extensive use of flexible packaging solutions in the medical and pharmaceutical sectors is driving market growth due to product variety, low weight, easy disposal, and the requirement of fewer raw materials. Pouches and bags were the market's most important product segment in 2020. These products are available in a variety of sizes and have a broad range of applications in a variety of end-use sectors, which drives their demand.
VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/medical-flexible-packaging-market
Segmental Analysis
The global medical flexible packaging market is segmented based on material, product, and end-user. By material, the product is segmented as plastics, paper, aluminium, and bioplastics. Plastics, is further segmented as polyvinyl chloride, polypropylene, polyethylene terephthalate, polyethylene, and others. Further, product is segmented as seals, high barrier films, wraps, pouches & bags, lids & labels, and others. High Barrier Films is further segregated as biaxially oriented polyethylene terephthalate (BOPET), ethylene vinyl alcohol (EVA), polyacrylonitrile, silicon oxide, aluminum oxide, polyvinylidene chloride, and others. End-use is further segmented as pharmaceutical manufacturing, medical device manufacturing, implant manufacturing, contract packaging, and others
Some of the leading competitors are Bemis Company, Inc., Dätwyler Holding, Inc., Becton, Dickinson & Company, Berry Global, Inc., Catalent, Inc., Coveris, Winpak Ltd., Sealed Air Corporation, and among others.
Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports
Some of the key observations regarding medical flexible packaging industry include:
- In June 2019, Amcor, announced acquisition of Bemis Company Inc. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symbol "AMCR" and the Australian Securities Exchange under the ticker symbol "AMC." Amcor is included in both the S&P 500 and S&P/ASX 200 indices.
- In January 2021, Catalent, Inc., announced signing agreement with Acorda Therapeutics, Inc. Under the terms of the agreement, Catalent will acquire Acorda Therapeutics’ 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, close to Boston Logan International Airport and the thriving biotechnology networks centered around Boston and Cambridge. The site operates best-in-class spray drying capacity, including GEA NIRO® PSD-1, PSD-4 and PSD-7 spray drying units, with the latter unit being the largest equipment of its kind in North America, and will provide Catalent with significant commercial-scale capacity for new customer programs. The facility will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging.
INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2665
BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2665
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting